Nefopam topical cream - ScarX Therapeutics

Drug Profile

Nefopam topical cream - ScarX Therapeutics

Alternative Names: SCX-001

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator ScarX Therapeutics
  • Class Antifibrotics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Beta catenin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypertrophic scars

Most Recent Events

  • 27 Jun 2017 ScarX Therapeutics completes enrolment in its phase I trial for Hypertrophic scars in Canada (NCT03036306)
  • 18 Aug 2016 Health Canada approves IND application for nefopam cream in Hypertrophic scars
  • 16 Feb 2016 Preclinical trials in Hypertrophic scars in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top